Biotech Values

[DewDiligence]

What GENR ought to do:

>>…any REAL GOOD NEWS about GENR seems to be a long way from where we are now (it seems to have little or NO CHANCE for SUCCESS, right?)<<

GENR is not yet roadkill, but things are starting to look desperate. What should GENR do to restore hope? Here’s a partial list:

1. The BOD should show Levitt the door and bring in a real CEO with industry credibility.

2. Scale back officer/director salaries, options, and bonuses to a level commensurate with the company’s resources and actual performance. GENR is not Amgen, and it shouldn’t act like Amgen in the compensation arena.

3. The new CEO should play straight with investors, which means an end to BS about programs lacking bona fide commercial prospects such as Lomucin, Trodusquemine, and Squalamine in cancer. (Seasoned investors are smarter than Levitt evidently thinks, and they are apt to find that Levitt’s BS about the dead-end programs casts guilt-by-association doubt on the AMD program.)

4. The new CEO should avoid overselling the clinical data obtained to date in AMD. It’s better to be candid and say that the company is working diligently to show a treatment benefit in their first randomized, controlled trial—instead of acting as though they have already accomplished this and are waiting to be “discovered” like a Hollywood starlet.

5. Accept an AMD partnership deal for modest up-front terms if a bona fide offer is made. It’s better to give away a substantial slice of the pie to an enterprising partner than to dilute existing shareholders into oblivion and risk having no pie at all if the next set of clinical data does not measure up.

JMHO, FWIW